Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company pioneering extended-release therapies through its proprietary DiffuSphere™ technology. This page provides investors and researchers with comprehensive access to verified company developments, including clinical trial progress, regulatory updates, and scientific advancements.
Our curated news collection offers timely updates on EPRX's innovative programs targeting osteoarthritis pain management and eosinophilic esophagitis treatment. Users will find detailed information about:
• Clinical trial results from ongoing studies including SPRINGBOARD (OA) and RESOLVE (EoE)
• Regulatory milestones and partnership announcements
• Technology developments in localized drug delivery systems
Bookmark this page for direct access to primary source updates about Eupraxia's progress in developing therapies that combine precise targeting with reduced systemic exposure. Check regularly for new developments in this clinical-stage biotech company's mission to address unmet medical needs through advanced drug delivery science.
Eupraxia Pharmaceuticals announced the expansion of its RESOLVE Phase 1b/2a trial for EP-104GI to treat eosinophilic esophagitis (EoE). Encouraging early-phase results with eight of nine patients responding positively and exhibiting good safety profiles spurred this decision. The expansion will allow for higher doses and longer follow-up periods, now up to 52 weeks. The study will include more participants, increasing from 12-15 to 27-33. Additional clinical sites will be established to support the new recruitment targets. The trial aims to gather data to support a potential registration trial in 2025.
Eupraxia Pharmaceuticals will host a virtual key opinion leader (KOL) event on May 29, 2024, at 10:00 AM ET to discuss their EP-104GI clinical development program for Eosinophilic Esophagitis (EoE). The event will feature Dr. Evan S. Dellon, a leading expert from the University of North Carolina, alongside company management. The focus will be on data from the Phase 1b/2a RESOLVE trial and the potential of Eupraxia's DiffuSphere™ technology to enhance treatment outcomes for EoE patients. A live Q&A session will follow.
Eupraxia Pharmaceuticals announced positive data from its Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE). Results from the first and second cohorts showed potential efficacy up to 24 weeks, with improved symptom outcomes and reduced eosinophil counts. The third cohort, receiving a higher dose, also reported symptom improvements at 12 weeks. The treatment demonstrated a strong safety profile with only mild to moderate adverse events. Eupraxia plans to continue data disclosure as the trial progresses.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announced that it will present initial results from its ongoing Phase 1b study of EP-104GI at the Digestive Disease Week (DDW) Annual Meeting 2024, held in Washington, D.C., from May 18-21, 2024.
The study focuses on treating eosinophilic esophagitis using EP-104GI, a long-acting injectable suspension of fluticasone propionate. Chief Scientific Officer Amanda Malone, PhD, will deliver a poster presentation on May 18, 2024.
The presentation details are: Abstract: 4031521, Session Type: Poster Session, Session Title: Eosinophilic Esophagitis and Gastroenteritis: Clinical, and Session Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4).
Further details will be available on Eupraxia's website.
Eupraxia Pharmaceuticals reported its first quarter 2024 financial results and provided a corporate update, highlighting achievements such as listing on Nasdaq, progress in clinical studies, and financial performance. Notable milestones include the presentation of positive clinical data, initiation of Phase 3 development programs, and securing funding through public offerings. The company's focus on optimizing drug delivery technology and advancing treatments for conditions like osteoarthritis shows promise for future growth and development.
Eupraxia Pharmaceuticals has announced the formation of a Clinical Advisory Board for its gastrointestinal program, specifically focusing on the EoE treatment. The board consists of renowned experts in the field who will guide the development of EP-104GI for eosinophilic esophagitis. The company aims to address the unmet medical needs of the EoE patient population with their proprietary DiffuSphere™ technology.
FAQ
What is the current stock price of Eupraxia Pharmac (EPRX)?
What is the market cap of Eupraxia Pharmac (EPRX)?
